Core Viewpoint - The Supervisory Board of Yuanli Chemical Group Co., Ltd. has expressed support for the company's 2025 employee stock ownership plan, emphasizing its role in enhancing employee motivation, cohesion, and overall competitiveness of the company [1] Summary by Relevant Sections - **Employee Stock Ownership Plan**: The plan aims to establish a long-term and effective incentive mechanism, which is expected to improve employee engagement and the company's governance level, promoting sustainable development [1] - **Compliance and Governance**: The Supervisory Board confirms that the plan adheres to relevant laws and regulations, ensuring that it does not harm the interests of the company and all shareholders [1] - **Participation Principles**: The plan is based on principles of legal compliance, voluntary participation, and self-borne risks, with no coercion or forced distribution of shares to employees [1]

Meeting Information - The shareholders' meeting of Yuanli Chemical Group Co., Ltd. is scheduled for September 16, 2025, at 14:30 [1] - The meeting will be held at the company's conference room in Changle County, Weifang City [1] - Voting will be conducted through a combination of on-site and online methods using the Shanghai Stock Exchange's network voting system [1] Voting Procedures - Shareholders can vote via the Shanghai Stock Exchange network voting system from 9:15 to 15:00 on the day of the meeting [1][2] - Specific voting times through the trading system are from 9:15-9:25, 9:30-11:30, and 13:00-15:00 [1] - Shareholders holding multiple accounts can aggregate their voting rights across all accounts [3] Agenda Items - The meeting will review several proposals related to the 2025 Employee Stock Ownership Plan, including the draft plan and its management measures [2][8] - Shareholders with a conflict of interest regarding the employee stock ownership plan are required to abstain from voting [2] Attendance Requirements - Only shareholders registered by the close of trading on September 9, 2025, are eligible to attend the meeting [3] - Shareholders can appoint proxies to attend and vote on their behalf [3] Registration Process - Corporate shareholders must provide specific documentation for registration, including a business license and identification [4] - Individual shareholders must present their stock account card and identification for registration [4]

Core Viewpoint - The company is proposing an employee stock ownership plan (ESOP) for 2025, which requires approval from the shareholders' meeting to be implemented. The plan's success is uncertain due to various factors, including employee participation and funding sources [1][2]. Group 1: Plan Overview - The ESOP is designed in accordance with relevant laws and regulations, including the Company Law and Securities Law of the People's Republic of China [2]. - The plan is voluntary, with a maximum of 111 employees participating, including key management and core personnel [2][9]. - The total funding to be raised through the plan is capped at 27.216 million yuan, with each share priced at 9.45 yuan [3][13]. Group 2: Funding and Share Allocation - The funding sources for the ESOP include employees' own funds and legally permitted methods, with no financial assistance provided by the company [3][12]. - The total number of shares held by the ESOP will not exceed 10% of the company's total equity, and individual employee holdings will not exceed 1% [4][9]. - The plan includes a reserve of 382,000 shares, accounting for 13.26% of the total shares, to attract and retain talent [3][11]. Group 3: Lock-up and Vesting Period - The ESOP has a duration of 80 months, with shares vesting in three phases: 30% after 12 months, 30% after 24 months, and 40% after 36 months [5][18]. - The plan allows for early termination or extension under certain conditions, subject to approval from the holders' meeting [17][23]. Group 4: Performance Assessment - The plan includes performance targets for both company and individual levels, with specific revenue growth rates set for the years 2025 to 2027 [19][20]. - If performance targets are not met, unvested shares may be repurchased by the company at the original investment amount plus interest [20][21]. Group 5: Management and Governance - The ESOP will be managed by a committee representing the participants, ensuring the protection of their rights and interests [22]. - Any changes to the plan must be approved by a two-thirds majority of the holders' meeting [23].

Core Points - The company, Yuanli Chemical Group Co., Ltd., held a staff representative meeting on August 27, 2025, to solicit opinions on the proposed 2025 Employee Stock Ownership Plan [1][2] - The Employee Stock Ownership Plan draft was approved unanimously by the staff representatives, indicating strong internal support for the initiative [2] Summary by Sections Employee Stock Ownership Plan - The 2025 Employee Stock Ownership Plan draft complies with relevant laws and regulations, including the Company Law and Securities Law of the People's Republic of China [1] - The plan aims to establish a profit-sharing mechanism among the company, shareholders, and employees, enhancing employee cohesion and company competitiveness [1] - The implementation of the plan is based on voluntary participation, ensuring that there is no coercion or forced distribution among employees [1]

Group 1 - The board meeting of Anhui Zhongdian Xinlong Technology Co., Ltd. was held on August 27, 2025, with all 9 directors present, complying with legal and regulatory requirements [1] - The board approved the 2025 semi-annual report and summary with a unanimous vote of 9 in favor, 0 against, and 0 abstentions [1] - The board also approved changes to the employee stock ownership plan with a vote of 5 in favor, 0 against, and 0 abstentions, with certain directors abstaining from the vote due to conflicts of interest [1][2] Group 2 - The changes to the employee stock ownership plan include a modification in the handling of shares, allowing the company to sell the shares instead of canceling them, with the proceeds going to the company [2] - Other terms of the employee stock ownership plan remain unchanged despite the modifications [2]

证券代码：002298 证券简称：中电鑫龙 编号：2025-054 安徽中电鑫龙科技股份有限公司（以下简称"公司"或"本公司"）2025 年第二次独立董事专门会议于 2025 年 8 月 27 日以通讯方式召开。本次会议应出 席独立董事 3 人，实际出席独立董事 3 人，全体独立董事共同推举许礼进先生召 集并主持本次会议。本次独立董事专门会议的召集、召开及表决程序符合《公司 法》、《公司章程》、《独立董事制度》、《独立董事专门会议制度》等有关规 定。 安徽中电鑫龙科技股份有限公司 二○二五年八月二十七日 经审查，全体独立董事认为：本次变更公司员工持股计划部分条款的事项符 合《公司法》《证券法》《关于上市公司实施员工持股计划试点的指导意见》《深 圳证券交易所上市公司自律监管指引第 1 号—主板上市公司规范运作》等相关 法律、法规、规范性文件有关规定，已取得了现阶段必要的批准与授权，并履行 了相应的审议程序，符合《试点指导意见》《自律监管指引第 1 号》等有关法 律、法规和规范性文件的规定，不存在损害公司及全体股东利益的情形。因此， 我们同意《关于变更公司员工持股计划部分条款的议案》，并同意提交公司第十 届董事会 ...

Meeting Overview - The third meeting of the 10th Supervisory Board of Anhui Zhongdian Xinlong Technology Co., Ltd. was held on August 27, 2025, with all three supervisors present, complying with the Company Law and Articles of Association [1][2] Resolutions Passed - The Supervisory Board unanimously approved the 2025 Half-Year Report and its summary, confirming that the report accurately reflects the company's actual situation without any false records or misleading statements [1] - The Supervisory Board approved the amendment of certain terms of the employee stock ownership plan, stating that the changes have received necessary approvals and do not harm the interests of the company or its shareholders, nor will they adversely affect the company's strategic development or financial status [2]

Investment Rating - The report maintains an "Outperform the Market" rating for the company [5][16][20]. Core Views - The company's revenue decreased slightly, with a transition from profit to loss. In H1 2025, the company achieved revenue of 1.295 billion yuan, a year-on-year decline of 8.23%. The net profit attributable to the parent company was -50.5 million yuan, a decrease of 96 million yuan year-on-year, aligning with market expectations [1][3][7]. - The decline in revenue is primarily attributed to the slower-than-expected conversion of new contracts. The gross profit margin fell by 4.11 percentage points to 40.33% [1][3][7]. - The company has 14 ongoing PPP projects, and new regulations from the Ministry of Finance are expected to improve cash flow and reduce impairment burdens [2][12][15]. - The company plans to repurchase shares worth 100-150 million yuan at a price not exceeding 29.5 yuan per share, which is seen as a positive signal for shareholder confidence [2][12][15]. Financial Performance Summary - For H1 2025, the company reported a revenue of 1.295 billion yuan, down 8.23% year-on-year. The revenue from Puyue Technology was 482 million yuan, a decline of 5.9%, accounting for 37% of total revenue [1][7]. - The gross profit margin for the instrument, software, and consumables segment was 44.55%, down 3.77 percentage points year-on-year. The operating service, testing service, and consulting service segment saw a revenue of 213 million yuan, down 11.83%, with a gross profit margin of 35.77%, down 4.03 percentage points [2][12]. - The company expects net profits for 2025-2027 to be 267 million, 344 million, and 415 million yuan, respectively, with year-on-year growth rates of 29.2%, 28.8%, and 20.6% [3][16]. Segment Performance - The revenue from the instrument, related software, and consumables business was 896 million yuan, down 7.39% year-on-year. The environmental equipment and engineering business generated 135 million yuan, down 2.3% [2][12]. Shareholder Confidence - The planned share repurchase is intended to boost shareholder confidence and is indicative of management's positive outlook on the company's future [2][12][15].

Core Points - Chengdu Xian Dao Pharmaceutical Development Co., Ltd. held its 23rd meeting of the second board of directors on August 26, 2025, with all 9 directors present, ensuring compliance with legal and regulatory requirements [1] - The board approved several key proposals, including the review of the 2025 semi-annual report and the special report on the use of raised funds [2][3] - The board also approved the cancellation of the supervisory board and amendments to the company's articles of association, which will be submitted for shareholder approval [2][3] - The board nominated candidates for the third board of directors, including both non-independent and independent directors, pending shareholder approval [3][4] - The board reviewed and approved the semi-annual evaluation report of the 2025 quality improvement and efficiency recovery action plan [4] - The board discussed the 2025 restricted stock incentive plan and its management methods, which will also require shareholder approval [5][6] - The board proposed to authorize the board to handle matters related to the 2025 employee stock ownership plan, pending shareholder approval [8][9]

Meeting Overview - The second meeting of the Supervisory Board of Chengdu XianDao Pharmaceutical Development Co., Ltd. was held on August 26, 2025, with all three supervisors present [1] - The meeting was convened in accordance with relevant laws and regulations, and the resolutions passed were deemed legal and effective [1] Resolutions Passed - The Supervisory Board approved the company's 2025 semi-annual report and its summary [2] - The board also approved the special report on the storage and actual use of the raised funds for the first half of 2025 [2] - A resolution was passed to cancel the Supervisory Board, amend the company’s articles of association, and remove the chairman of the Supervisory Board, pending approval from the shareholders' meeting [2][3] - The board approved the draft of the 2025 restricted stock incentive plan and its summary, which will also be submitted for shareholder approval [3] - The implementation assessment management measures for the 2025 restricted stock incentive plan were approved, pending shareholder approval [3] - The verification of the list of incentive objects for the 2025 restricted stock incentive plan was also approved [3] - The draft of the 2025 employee stock ownership plan and its summary could not be resolved due to two supervisors abstaining from voting, and it will be submitted for shareholder approval [4] - The management measures for the 2025 employee stock ownership plan could not be resolved for the same reason and will also be submitted for shareholder approval [4]